Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860564 | 1.00 | CHRM1 (0.48) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL5822580 | 0.98 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3861604 | 0.86 | CA2 (0.48) | HDAC2FOLH1NOD1SLC1A3SLC1A2 | |
| SCHEMBL3861605 | 0.86 | CA2 (0.48) | HDAC2FOLH1NOD1SLC1A3SLC1A2 | |
| SCHEMBL21689984 | 0.85 | GPR84 (0.50) | FOLH1NOD1GRIK1SLC1A2SLC1A1 | |
| SCHEMBL23130995 | 0.84 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL8413851 | 0.84 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL148236 | 0.84 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL22891943 | 0.84 | FOLH1 (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL23374706 | 0.84 | FOLH1 (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461332-A2 | PRODUCTION OF CHIRALLY PURE ALPHA-AMINO ACIDS AND N-SULFONYL ALPHA-AMINO ACIDS | Wyeth (US) | 2004-09-29 | — | — | EP | claimed |
| US-6657070-B2 | Such as N-((5-chloro-2-thienyl)sulfonyl)-3-ethylnorvaline and 5-chloro-N-((S)-2-ethyl-1-formylbutyl)thiophene-2-sulfonamide via reacting aldehyde, cyanide salt, and alpha-methylbenzylamine | WYETH | 2003-12-02 | — | — | US | claimed |
| WO-2003050062-A2 | PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS | WYETH (US) | 2003-06-19 | — | — | WO | claimed |
| US-20030013892-A1 | Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids | WYETH | 2003-01-16 | — | — | US | claimed |
| EP-4172180-A1 | USES, METHODS AND PRODUCTS RELATING TO OLIGOMERIC LIPOPOLYSACCHARIDE BINDING PROTEINS | Universitetet I Oslo (NO) | 2023-05-03 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021260144-A1 | USES, METHODS AND PRODUCTS RELATING TO OLIGOMERIC LIPOPOLYSACCHARIDE BINDING PROTEINS | UNIVERSITETET I OSLO (NO) | 2021-12-30 | — | — | WO | disclosed |
| WO-2016090305-A1 | SOLID-PHASE SYNTHESIS OF PEPTIDES CONTAINING BULKY DEHYDROAMINO ACIDS | CASTLE STEVEN L (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015011615-A1 | MIXTURES COMPRISING A TRICHODERMA STRAIN AND A PESTICIDE | BASF CORPORATION (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-2471363-A1 | Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants | Bayer CropScience AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012004287-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | MERCK SERONO S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | disclosed |
| CN-1901797-A | Biological immune-aggressin composition for inhibiting xanthomonas infection in crops | BIOSYS CORP (US) | 2007-01-24 | — | — | CN | disclosed |
| EP-1718144-A2 | BIOIMMUNE-AGGRESSIN COMPOSITION FOR SUPPRESSION OF XANTHOMONAD INFECTIONS IN AGRICULTURE CROPS | BIOSYS CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20060165818-A1 | Bioimmune-aggressin composition for suppression of Xanthomonad infections in agriculture crops | BIOSYS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1677816-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006056009-A1 | PEPTIDES HAVING ADHESIVE PROPERTIES FOR USE IN SOLID PHASE ASSAY AND CHEMICAL POLYMER SYNTHESIS REGIMES. | HEPGENICS PTY LTD (AU) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005069790-A2 | BIOIMMUNE-AGGRESSIN COMPOSITION FOR SUPPRESSION OF XANTHOMONAD INFECTIONS IN AGRICULTURE CROPS | BIOSYS CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050153005-A1 | Bioimmune-aggressin composition for suppression of xanthomonad infections in agriculture crops | BIOSYS CORPORATION | 2005-07-14 | — | — | US | disclosed |
| WO-2005032578-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013892-A1 | Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids | DNPEP, EDNRB, PNMT | CHRM1 237/4885AKR1A1 820/4885CHRM3 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.